Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma Inc (LYEL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $213M; returns 1 day +0.1%, 1 week +15.6%, 1 year -48.7%.

Lyell Immunopharma Inc. (LYEL) is a clinical-stage biopharmaceutical company focused on developing T-cell reprogramming technologies to create durable CAR T-cell and TIL therapies for patients with solid tumors and hematologic malignancies.

Groups LYEL belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Immunotherapy
• Healthcare
• Life Sciences
• Biopharmaceutical
• Cancer Therapeutics
• Hematologic Malignancies
• R&D
• Clinical Stage

LYEL financial model: income statement, cash flow and balance sheet